Evotec Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Evotec ha un patrimonio netto totale di €968.5M e un debito totale di €470.1M, che porta il suo rapporto debito/patrimonio netto a 48.5%. Le sue attività totali e le sue passività totali sono rispettivamente €2.0B e €1.0B.

Informazioni chiave

48.5%

Rapporto debito/patrimonio netto

€470.05m

Debito

Indice di copertura degli interessi	n/a
Contanti	€303.27m
Patrimonio netto	€968.47m
Totale passività	€1.02b
Totale attività	€1.99b

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( €698.1M ) di EVT superano le sue passività a breve termine ( €333.6M ).

Passività a lungo termine: Le attività a breve termine di EVT ( €698.1M ) superano le sue passività a lungo termine ( €688.7M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 17.2% ) di EVT è considerato soddisfacente.

Riduzione del debito: Il rapporto debito/patrimonio netto di EVT si è ridotto da 68.8% a 48.5% negli ultimi 5 anni.

Copertura del debito: Il flusso di cassa operativo di EVT è negativo, pertanto il debito non è ben coperto.

Copertura degli interessi: Dati insufficienti per determinare se i pagamenti degli interessi sul debito di EVT siano ben coperti dall'EBIT.

Evotec Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Evotec SE announced delayed 20-F filing

Recent updates

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) cancelled the acquisition of Evotec SE (XTRA:EVT).

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) cancelled the acquisitionn of Evotec SE (XTRA:EVT).

Recursion Pharmaceuticals, Inc. (NasdaqGS:RXRX) completed the acquisition of Exscientia plc (NasdaqGS:EXAI).

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) made a non-binding expression of interest to acquire Evotec SE (XTRA:EVT) for €2 billion.

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) made a non-binding expression of interest to acquire Evotec SE (XTRA:EVT) for €2 billion.

Triton Reportedly Weighs Takeover Deal for Drug Developer Evotec

Monacum Partners GmbH acquired Evotec Drug Substance (Germany) GmbH from Evotec SE (XTRA:EVT).

Price target decreased by 22% to €10.65

Evotec SE Announces Change in Management Board, Effective 01 October 2024

Price target decreased by 11% to €13.64

Second quarter 2024 earnings: EPS misses analyst expectations

Evotec SE Updates Earnings Guidance for the Fiscal Year 2024

Price target decreased by 7.3% to €19.26

Aurobac Therapeutics, founded by Boehringer Ingelheim, bioMerieux and Evotec, Names Scientific Advisory Board

Evotec SE to Report Nine Months, 2024 Results on Nov 08, 2024

Evotec SE, Annual General Meeting, Jun 10, 2024

Evotec SE announced delayed 20-F filing

Full year 2023 earnings: EPS misses analyst expectations

Evotec SE Provides Earnings Guidance for the Year 2024

Evotec SE Welcomes Aurélie Dalbiez as Chief People Officer, Effective 15 June 2024

Evotec SE to Report Fiscal Year 2023 Results on Apr 24, 2024

Price target decreased by 7.5% to €23.00

Price target decreased by 7.6% to €23.67

Price target decreased by 8.3% to €24.88

Evotec SE to Report Q1, 2024 Results on May 22, 2024

Price target decreased by 9.1% to €27.14

Evotec SE Announces Zhejiang Jingxin Pharmaceutical Co., Ltd Receives Approval for EVT201 in China

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Evotec SE to Report Nine Months, 2023 Results on Nov 08, 2023

Second quarter 2023 earnings released: €0.084 loss per share (vs €0.16 loss in 2Q 2022)

Evotec SE (XTRA:EVT) acquired remaining 50% stake in NephTera Gmbh from Vifor (International) AG for €1.65 million.

Evotec SE Provides Revenue Guidance for the Full Year 2023

Evotec SE Revises Earnings Guidance for the Fiscal Year 2023

Evotec SE, Annual General Meeting, Jun 20, 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased by 9.8% to €24.73

Evotec SE Appoints Laetitia Rouxel as Member of the Management Board, Effective 01 April 2023

Price target decreased to €26.72

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Evotec SE Reaffirms Earnings Guidance for the Full Year 2022

Price target decreased to €30.94

Evotec Launches PanOmics Data Analysis Platform PanHunter At Bio-IT World

Price target decreased to €32.50

Evotec SE (XTRA:EVT) agreed to acquire Central Glass Germany GmbH from Central Glass Co., Ltd. (TSE:4044) for €1.

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Evotec SE Revises Revenue Guidance for the Full Year 2022

Evotec SE (XTRA:EVT) completed the acquisition of Rigenerand S.R.L. from Xyence Capital SGR and others.

Evotec Se Appoints Camilla Macapili Languille as New Member of Supervisory Board

Evotec SE (XTRA:EVT) agreed to acquire Rigenerand S.R.L. for €25 million.

Investor sentiment improved over the past week

Evotec SE Confirms Revenue Guidance for 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Evotec Se Provides Revenue Guidance for 2022

Now 21% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Evotec SE Announces That the Company Has Been Informed by Bayer About A Decision to Discontinue the Development of the Investigational P2X3 Receptor Antagonist Eliapixant

Evotec SE to Report Q1, 2022 Results on May 11, 2022

Evotec Receives € 7.5 Million Grant for Development of Covid-19 Therapeutic from German Federal Ministry of Education and Research

Price target increased to €42.92

Third quarter 2021 earnings released: EPS €0.82 (vs €0.009 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS €0.36 (vs €0.065 loss in 2Q 2020)

Evotec SE Provides Revenue Guidance for the Full Year of 2021

Evotec SE (XTRA:EVT) acquired Campus Levi-Montalcini from GlaxoSmithKline plc (LSE:GSK).

Independent Chairman of Supervisory Board Wolfgang Plischke has left the company

Price target increased to €35.78

First quarter 2021 earnings released: EPS €0.32 (vs €0.11 in 1Q 2020)

Evotec SE Reports Revenue Guidance for Revenue for the Full-Year 2021

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane